MX2021009499A - Inhibidores de arginasa y metodos de uso de estos. - Google Patents

Inhibidores de arginasa y metodos de uso de estos.

Info

Publication number
MX2021009499A
MX2021009499A MX2021009499A MX2021009499A MX2021009499A MX 2021009499 A MX2021009499 A MX 2021009499A MX 2021009499 A MX2021009499 A MX 2021009499A MX 2021009499 A MX2021009499 A MX 2021009499A MX 2021009499 A MX2021009499 A MX 2021009499A
Authority
MX
Mexico
Prior art keywords
methods
compounds
formula
arginase inhibitors
arginase
Prior art date
Application number
MX2021009499A
Other languages
English (en)
Inventor
Iain Simpson
Maurice Raymond Verschoyle Finlay
Sameer Kawatkar
Scott Nathan Mlynarski
Tyler Grebe
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2021009499A publication Critical patent/MX2021009499A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/025Boronic and borinic acid compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se divulgan compuestos de fórmula (Ib) o (Vc), o una sal farmacéuticamente aceptable de estos, composiciones farmacéuticas que comprenden compuestos de fórmula (Ib) o (Vc) y métodos para utilizar estos para tratar el cáncer, una enfermedad inflamatoria respiratoria e inhibir la arginasa: (ver Fórmulas) (Ib), o (Vc); donde R1 es -H o -C(O)CH(R1a)NHR1b; y R1a se selecciona entre -H, -alquilo (C1-C4) y CH2OR1c; R1b es -H; o como alternativa, R1a y R1b, junto con el átomo al que están unidos, forman un anillo heterocíclico de 5 miembros; y R1c es H o -CH3.
MX2021009499A 2019-02-08 2020-02-07 Inhibidores de arginasa y metodos de uso de estos. MX2021009499A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962802765P 2019-02-08 2019-02-08
PCT/IB2020/050982 WO2020161675A1 (en) 2019-02-08 2020-02-07 Arginase inhibitors and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2021009499A true MX2021009499A (es) 2021-09-08

Family

ID=69770954

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021009499A MX2021009499A (es) 2019-02-08 2020-02-07 Inhibidores de arginasa y metodos de uso de estos.

Country Status (29)

Country Link
US (1) US20220106335A1 (es)
EP (1) EP3921033B1 (es)
JP (1) JP2022521474A (es)
KR (1) KR20210126044A (es)
CN (1) CN113395996B (es)
AU (1) AU2020218651B2 (es)
BR (1) BR112021015581A2 (es)
CA (1) CA3127755A1 (es)
CL (1) CL2021002056A1 (es)
CO (1) CO2021011039A2 (es)
CR (1) CR20210463A (es)
DK (1) DK3921033T3 (es)
DO (1) DOP2021000166A (es)
EA (1) EA202192114A1 (es)
ES (1) ES2960034T3 (es)
FI (1) FI3921033T3 (es)
HR (1) HRP20231092T1 (es)
HU (1) HUE062968T2 (es)
IL (1) IL285108B1 (es)
LT (1) LT3921033T (es)
MA (1) MA56324B1 (es)
MX (1) MX2021009499A (es)
PE (1) PE20220280A1 (es)
PL (1) PL3921033T3 (es)
PT (1) PT3921033T (es)
RS (1) RS64781B1 (es)
SG (1) SG11202108503PA (es)
SI (1) SI3921033T1 (es)
WO (1) WO2020161675A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202228720A (zh) 2020-12-22 2022-08-01 波蘭商昂科艾倫迪治療法股份公司 精胺酸酶抑制劑及其使用方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9901572D0 (sv) * 1999-05-03 1999-05-03 Astra Ab New compounds
SE0300907D0 (sv) * 2003-03-31 2003-03-31 Astrazeneca Ab Novel compounds
WO2010085797A2 (en) * 2009-01-26 2010-07-29 The Trustees Of University Of Pennsylvania Arginase inhibitors and methods of use
EP2560978B1 (en) * 2010-04-22 2019-01-30 Mars, Incorporated Inhibitors of arginase and their therapeutic applications
EP3719024A1 (en) * 2010-10-26 2020-10-07 Mars, Incorporated Arginase inhibitors as therapeutics
MX343534B (es) * 2011-10-19 2016-11-09 Mars Inc Inhibidores de arginasa y sus aplicaciones terapeuticas.
MX2015007797A (es) * 2012-12-17 2015-10-05 Parion Sciences Inc Compuestos de 3,5-diamino-6-cloro-n-(n-(4-fenilbutil) carbamimidoil) pirazin-2-carboxamida.
PL410665A1 (pl) * 2014-12-29 2016-07-04 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
WO2017175185A1 (en) * 2016-04-08 2017-10-12 Novartis Ag Heteroaryl butanoic acid derivatives as lta4h inhibitors
SG10201911243WA (en) * 2016-12-22 2020-02-27 Calithera Biosciences Inc Compositions and methods for inhibiting arginase activity
CN108794517B (zh) * 2017-04-27 2021-03-30 南京谷睿生物科技有限公司 一种精氨酸酶抑制剂及其制备方法与用途
WO2019205979A1 (zh) * 2018-04-27 2019-10-31 四川科伦博泰生物医药股份有限公司 非天然氨基酸类衍生物、包含其的药物组合物及其制备方法和用途

Also Published As

Publication number Publication date
CL2021002056A1 (es) 2022-03-04
HUE062968T2 (hu) 2023-12-28
CN113395996B (zh) 2024-05-28
BR112021015581A2 (pt) 2021-10-05
DOP2021000166A (es) 2021-09-30
IL285108B1 (en) 2024-06-01
US20220106335A1 (en) 2022-04-07
CO2021011039A2 (es) 2021-09-09
MA56324B1 (fr) 2023-10-31
CR20210463A (es) 2021-10-15
PE20220280A1 (es) 2022-02-25
CN113395996A (zh) 2021-09-14
EA202192114A1 (ru) 2021-12-01
JP2022521474A (ja) 2022-04-08
KR20210126044A (ko) 2021-10-19
SI3921033T1 (sl) 2023-11-30
SG11202108503PA (en) 2021-09-29
AU2020218651B2 (en) 2023-01-12
CA3127755A1 (en) 2020-08-13
HRP20231092T1 (hr) 2023-12-22
WO2020161675A1 (en) 2020-08-13
FI3921033T3 (fi) 2023-09-15
EP3921033A1 (en) 2021-12-15
EP3921033B1 (en) 2023-07-26
AU2020218651A1 (en) 2021-09-30
DK3921033T3 (da) 2023-10-16
IL285108A (en) 2021-09-30
PT3921033T (pt) 2023-10-11
LT3921033T (lt) 2023-09-25
ES2960034T3 (es) 2024-02-29
PL3921033T3 (pl) 2024-01-15
RS64781B1 (sr) 2023-11-30

Similar Documents

Publication Publication Date Title
JOP20200197A1 (ar) مثبطات أرجيناز وطرق لاستخدامها
MX2021013472A (es) Moduladores de thr-? y metodos de uso de estos.
MX2020005363A (es) Compuestos heterociclicos como inhibidores de prmt5.
MX2012003499A (es) Inhibidores de demetilasa-1 especificos de lisina y su uso.
WO2009118567A3 (en) Pyrimidines, triazines and their use as kinase inhibitors
MX2009012283A (es) Derivado heterociclico que contiene nitrogeno que tiene actividad inhibitoria de 11beta-hidroxiesteroide-deshidrogenasa tipo 1.
IL185844A0 (en) I-acetic acid-indole derivatives with pgd2 antagonist activity
RS53017B (en) SPIROPIPERIDINE COMPOUNDS AS ANTAGONISTS OF ORL 1 RECEPTORS
NO20071921L (no) Fremgangsmater for behandling av epileptogenese og epilepsi
NO20081582L (no) Benzamidforbindelser anvendbare som histon-deacetylaseinhibitorer
MX341341B (es) Derivados de benzamida y su uso como inhibidores de proteina de choque termico 90 kda (hsp90).
TW200744575A (en) Methods of treating epileptogenesis
WO2009047615A3 (en) Novel histone deacetylase inhibitors
MX2019008331A (es) Derivados de amino-imidazopiridina novedosos como inhibidores de cinasa de janus y uso farmacéutico de estos.
MX2021009499A (es) Inhibidores de arginasa y metodos de uso de estos.
MX2022003617A (es) Derivados heterociclicos, composiciones farmaceuticas y su uso en el tratamiento o mejora del cancer.
JOP20220084A1 (ar) مشتقات 5-أوكسا- 2- آزا سبيرو [3.4] أوكتان كناهضات لـ m4
EA202091886A1 (ru) Ингибиторы аргиназы и способы их применения
CY1112596T1 (el) Νεες ενωσεις και χρηση αυτων
MX2022007044A (es) Compuesto y composicion como inhibidor de cinasa del receptor de los factores de crecimiento derivados de las plaquetas (pdgf).
NZ767738B2 (en) Arginase inhibitors and methods of use thereof
EA201100360A1 (ru) Производные аминоспиртов, предназначенные для лечения демиелинизирующих периферических невропатий
MX2022000904A (es) Inhibidores de arginasa y métodos de uso de estos.
RU2015151257A (ru) Фармацевтическое применение соединения гексагидродибензо[a, g]хинолизина
MX2022001412A (es) Compuestos de 7,8-dihidro-4h-pirazolo[4,3-c]azepina-6-ona.